Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism;Partiäle acenocoumarol- en fenprocoumonresistentie door enzympolymorfisme

Nederlands Tijdschrift voor Geneeskunde

Volumn 150, Issue 38, 2006, Pages 2095-2098

  Wilms, E B ^a,b   Veldkamp, R F ^b   Van Meegen, E ^c   Touw, D J ^a  

^a Apotheek Haagse Ziekenhuizen   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c Stichting Rode Kruis Trombosedienst 's Gravenhage en Omstreken   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; CARVEDILOL; FUROSEMIDE; IRBESARTAN; PANTOPRAZOLE; PHENPROCOUMON; PHYTOMENADIONE; PRAVASTATIN; SPIRONOLACTONE; TEMAZEPAM; ANTICOAGULANT AGENT; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; VITAMIN K GROUP;

AGED; ANTICOAGULATION; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME POLYMORPHISM; HEART INFARCTION; HUMAN; MALE; BLOOD; DRUG RESISTANCE; GENETIC POLYMORPHISM; GENETICS; TREATMENT OUTCOME;

ACENOCOUMAROL; AGED; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; MYOCARDIAL INFARCTION; PHENPROCOUMON; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; VITAMIN K;

EID: 33749354898     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Stafford DW. The vitamin K cycle. J Thromb Haemost. 2005;3:1873-8.
2. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 2004;103:2630-5.
3. Iersel MB van, Blenke AAM, Kremer HPH, Hekster YA. Een patiënt met verminderde gevoeligheid voor acenocoumarol tijdens gebruik van sondevoeding. Ned Tijdschr Geneeskd. 2004;148:1155-7.
4. Pedersen FM, Hamberg O, Hess K, Ovesen L. The effect of dietary vitamin K on warfarin-induced anticoagulation. J Intern Med. 1991;229:517-20.
5. Informatorium medicamentorum. Den Haag: Winap; 2005.
6. O'Reilly RA, Aggeler PM, Hoag MS, Leong LS, Kropatkin ML. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. The first reported kindred. N Engl J Med. 1964;271:809-15.
7. O'Reilly RA. The second reported kindred with hereditary resistance to oral anticoagulant drugs. N Engl J Med. 1970;282:1448-51.
8. Lewis RJ, Spivack M, Spaet TH. Warfarin resistance. Am J Med. 1967;42:620-4.
9. Alving BM, Strickler MP, Knight RD, Barr CF, Berenberg JL, Peck CC. Hereditary warfarin resistance. Investigation of a rare phenomenon. Arch Intern Med. 1985;145:499-501.
10. Kereveur A, Leclercq M, Trossaert M, Dupeyron JP, Parent F, Horellou MH, et al. Vitamin K metabolism in a patient resistant to vitamin K antagonists. Haemostasis. 1997;27:168-73.
11. Bodin L, Horellou MH, Flaujac C, Loriot MA, Samama MM. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost. 2005;3:1533-5.
12. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537-41.
13. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-93.
14. Kohn MH, Pelz HJ. A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood. 2000;96:1996-8.
15. Greaves JH, Ayres P. Heritable resistance to warfarin in rats. Nature. 1967;215:877-8.
16. Reitsma PH, Heijden JF van der, Groot AP, Rosendaal FR, Büller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2005;2:e312.